pepmg_

Study summary · research use only

Tirzepatide as an Insulin Sensitizer.

Study · human · The Journal of clinical endocrinology and metabolism · 2022 · DOI 10.1210/clinem/dgab803 · PMID 34788445

Read the full study on PubMed ↗ Open-access full text ↗

pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.